This article discusses a recently approved prescription medication. It is not medical advice. Decisions about any prescription drug should be made with a qualified healthcare provider.
In December 2025, the FDA approved NEREUS (tradipitant) for the prevention of vomiting induced by motion. It's the first genuinely new pharmacological treatment for motion sickness to reach approval in over four decades — since the scopolamine patch was approved in 1979. That's a long gap, and the approval has generated significant interest from people who've found existing options inadequate.
This article explains what tradipitant is, how it works, what the clinical trials actually showed, and what it doesn't do — which matters as much as what it does.
Why This Is Significant
The motion sickness treatment landscape has been static for a long time. The main options — antihistamines like dimenhydrinate (Dramamine) and meclizine (Bonine), and the scopolamine patch — have been around for decades. They work through relatively blunt mechanisms and come with side effects, particularly sedation, that limit their usefulness.
Why medication effects vary between individuals is a consistent theme with the older drugs: they're effective for some people, modestly helpful for others, and nearly useless for a portion of sufferers who don't respond to their mechanisms. A drug that works through a different pathway offers a meaningful alternative for that last group.
How Tradipitant Works: A Different Mechanism
Antihistamines work by suppressing the histamine signaling that plays a role in the vestibular pathway to nausea. Scopolamine works by blocking muscarinic acetylcholine receptors, dampening the vestibular system's communication with the brainstem.
Tradipitant works through neither of these pathways. It's a neurokinin-1 (NK-1) receptor antagonist — it blocks the NK-1 receptor in the central nervous system, which is activated by a neurotransmitter called substance P. When sensory conflict activates the nausea response, the chain of events involves substance P binding to NK-1 receptors in the brainstem. Tradipitant blocks that binding.
This is the same general mechanism used in some antiemetic drugs prescribed for chemotherapy-induced nausea. The application to motion sickness is new, but the pharmacology is well-understood from other contexts.
What the Clinical Trials Actually Showed
The FDA approval was based primarily on two Phase III trials — Motion Syros and Motion Serifos — both conducted as real-world provocation studies aboard boats. Participants had documented histories of motion sickness and were randomly assigned to receive tradipitant (at either 85mg or 170mg) or placebo roughly 60 minutes before a 2–5 hour boat trip in variable sea conditions.
In Motion Syros, vomiting occurred in 18–19% of tradipitant recipients compared to 44% in the placebo group. In Motion Serifos, the numbers were 10–18% versus 38%. Those represent risk reductions of roughly 50–70% for vomiting specifically.
The important nuance: the primary endpoint was vomiting, not nausea. In both trials, the secondary endpoint of worst nausea score did not reach statistical significance. The scores were nearly identical between the tradipitant and placebo groups.
This is a meaningful distinction. Tradipitant appears to be considerably more effective at preventing the vomiting response than at preventing the subjective experience of nausea. For many people who get motion sick, nausea is the main issue — the vomiting, if it happens at all, is the endpoint they'd like to avoid but aren't necessarily expecting. For others, severe vomiting is precisely the problem that makes travel impossible. The drug's profile is clearly more useful for the latter group.
Side Effects
The most commonly reported side effects in clinical trials were somnolence (drowsiness), headache, and fatigue — occurring in at least 5% of recipients. Drowsiness is shared with the older antihistamines, though the mechanism is different. The prescribing information includes a warning about impaired ability to drive or operate heavy machinery.
The FDA's approval was for acute use — single-dose prevention before a motion-provoking event — not ongoing use. Vanda Pharmaceuticals (the maker) and the FDA agreed that motion sickness is an acute condition and the drug shouldn't be taken for extended periods.
What It Doesn't Do
Tradipitant is a prescription drug indicated specifically for adults. It requires taking on an empty stomach — at least one hour before or two hours after a full meal — approximately 60 minutes before the anticipated exposure. That dosing window matters. It's not a rescue medication for someone already mid-symptom.
As of early 2026, the drug had been approved but commercial launch was still pending. Availability and insurance coverage were expected to develop over the months following approval.
It also doesn't change the underlying sensory conflict that causes motion sickness in the first place. Like all current medications, it addresses one part of the cascade — in this case, the NK-1 receptor activation that drives vomiting — without eliminating the experience of discomfort or the vestibular processing demands that create it.
How It Compares to Existing Options
The comparison between Dramamine, Bonine, and scopolamine has long been the main choice for people using medication for motion sickness. Tradipitant adds a meaningful fourth option, particularly for people who:
It's not a replacement for the older options for everyone. For someone who finds meclizine effective and well-tolerated, there's no reason to switch. But for the subset of sufferers for whom current options haven't worked, tradipitant represents a genuinely different pharmacological approach — the first to reach the market in four decades.
The larger mechanism story is consistent with what why motion sickness solutions work differently for different people describes: there's no single pathway to motion sickness, and drugs targeting different parts of the system will help different people. Tradipitant extends the menu of options, which is useful precisely because no option works universally.
